134 related articles for article (PubMed ID: 37577829)
1. The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review.
Boustany A; Rahhal R; Mitri J; Onwuzo S; Abou Zeid HK; Baffy G; Martel M; Barkun AN; Asaad I
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1067-1074. PubMed ID: 37577829
[TBL] [Abstract][Full Text] [Related]
2. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis.
Noorian S; Jeon Y; Nguyen MT; Sauk J; Limketkai BN
Inflamm Bowel Dis; 2022 Jun; 28(6):878-887. PubMed ID: 34374782
[TBL] [Abstract][Full Text] [Related]
3. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.
Carr RM; Patel A; Bownik H; Oranu A; Kerner C; Praestgaard A; Forde KA; Reddy KR; Lichtenstein GR
Dig Dis Sci; 2017 May; 62(5):1354-1361. PubMed ID: 28265826
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.
Abenavoli L; Spagnuolo R; Scarlata GGM; Scarpellini E; Boccuto L; Luzza F
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003983
[No Abstract] [Full Text] [Related]
5. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease.
Zou ZY; Shen B; Fan JG
Inflamm Bowel Dis; 2019 Oct; 25(11):1764-1772. PubMed ID: 30918952
[TBL] [Abstract][Full Text] [Related]
6. Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: a systematic review.
Spagnuolo R; Abenavoli L; Corea A; Larussa T; Mancina RM; Cosco C; Luzza F; Doldo P
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5818-5825. PubMed ID: 34604973
[TBL] [Abstract][Full Text] [Related]
7. Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-analysis.
Trivedi HD; Lopes EW; Glissen Brown J; Dudani S; Lai M; Feuerstein JD; Pierce TT
J Clin Gastroenterol; 2023 Jul; 57(6):610-616. PubMed ID: 35648974
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
Zamani M; Alizadeh-Tabari S; Singh S; Loomba R
Aliment Pharmacol Ther; 2022 Apr; 55(8):894-907. PubMed ID: 35274325
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease.
Sartini A; Gitto S; Bianchini M; Verga MC; Di Girolamo M; Bertani A; Del Buono M; Schepis F; Lei B; De Maria N; Villa E
Cell Death Dis; 2018 Jan; 9(2):87. PubMed ID: 29367619
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.
Magrì S; Paduano D; Chicco F; Cingolani A; Farris C; Delogu G; Tumbarello F; Lai M; Melis A; Casula L; Fantini MC; Usai P
World J Gastroenterol; 2019 Oct; 25(37):5676-5686. PubMed ID: 31602167
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors.
Principi M; Iannone A; Losurdo G; Mangia M; Shahini E; Albano F; Rizzi SF; La Fortezza RF; Lovero R; Contaldo A; Barone M; Leandro G; Ierardi E; Di Leo A
Inflamm Bowel Dis; 2018 Jun; 24(7):1589-1596. PubMed ID: 29688336
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Lin A; Roth H; Anyane-Yeboa A; Rubin DT; Paul S
Inflamm Bowel Dis; 2021 May; 27(6):947-955. PubMed ID: 32780094
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.
Papaefthymiou A; Potamianos S; Goulas A; Doulberis M; Kountouras J; Polyzos SA
J Crohns Colitis; 2022 Jun; 16(5):852-862. PubMed ID: 34972203
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.
Glassner K; Malaty HM; Abraham BP
Inflamm Bowel Dis; 2017 Jun; 23(6):998-1003. PubMed ID: 28511199
[TBL] [Abstract][Full Text] [Related]
17. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
[TBL] [Abstract][Full Text] [Related]
18. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis.
Lapumnuaypol K; Kanjanahattakij N; Pisarcik D; Thongprayoon C; Wijarnpreecha K; Cheungpasitporn W
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):854-860. PubMed ID: 29697458
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of liver abnormalities in inflammatory bowel disease patients.
McHenry S
Curr Opin Gastroenterol; 2023 Jul; 39(4):287-293. PubMed ID: 37144524
[TBL] [Abstract][Full Text] [Related]
20. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review.
Martínez-Domínguez SJ; García-Mateo S; Laredo V; Gargallo-Puyuelo CJ; Gallego Llera B; López de la Cruz J; Gomollón F
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
